AstraZeneca plans to build a $2.5 billion research and development center in Beijing, the Britain-based multinational ...

Johnson & Johnson will invest $55 billion in the U.S. over the next four years. The announcement comes a month after Eli ...

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and ...

The pharma is paying up to $1 billion to buy the Belgian startup, whose technology it sees as useful in treating cancer and ...

In addition to a continued focus on growing drug pipelines, and the increasing use of artificial intelligence (AI) and data ...

AstraZeneca will pay Bristol-Myers Squibb ... strengthen the portfolio we have built to help patients with diabetes by building on the success Amylin has had with its GLP-1 franchise.

AstraZeneca investing $2.5 billion in China as drugmaker seeks to recover from scandals AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the ...

AstraZeneca to buy EsoBiotec for up to $1 billion Deal aims to enhance cancer cell therapy capabilities AstraZeneca secures global rights to Alteogen's ALT-B4 enzyme AstraZeneca shares up almost ...

From STAT’s Andrew Joseph: AstraZeneca said this morning it was buying the Belgian cell therapy company EsoBiotec for $425 million upfront, building out another cancer-targeting approach.

AstraZeneca bought Belgian biotech company EsoBiotec in a deal valued at up to $1 billion, to expand its cell-therapy portfolio. The British pharma company said Monday that it will pay $425 ...

By leveraging our cutting-edge discovery capabilities and AstraZeneca’s expertise in drug development, we aim to accelerate the creation of transformative therapies for patients with high unmet ...